Novartis | NVS - Equity Capital And Reserves


Novartis reported $44.33B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Amgen USD 8.66B 961M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Bausch Health Companies USD -554M 910M Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Canopy Growth CAD 736.01M 247.04M Sep/2025
Corcept Therapeutics USD 631.9M 3.89M Sep/2025
Drreddys Laboratories INR 4.14B 107.72M Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Glaxosmithkline GBP 21.7B 7.35B Sep/2025
J&J USD 78.47B 0 Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Novartis USD 44.33B 2.28B Sep/2025
Pacira USD 727.21M 30.55M Sep/2025
Perrigo USD 4.45B 25.8M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Phibro Animal Health USD 332.36M 20.68M Dec/2025
Prestige Brands USD 1.83B 4.48M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Sanofi EUR 71.71B 14.25B Dec/2025
Supernus Pharmaceuticals USD 1.05B 14.23M Sep/2025
Zoetis USD 3.33B 2.07B Dec/2025